Talphera Inc. (TLPH)vsViatris Inc (VTRS)
TLPH
Talphera Inc.
$0.80
+9.08%
HEALTHCARE · Cap: $34.03M
VTRS
Viatris Inc
$13.50
+1.05%
HEALTHCARE · Cap: $15.39B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 51070971% more annual revenue ($14.30B vs $28,000). TLPH leads profitability with a 0.0% profit margin vs -24.6%. VTRS earns a higher WallStSmart Score of 50/100 (C-).
TLPH
Avoid23
out of 100
Grade: F
VTRS
Buy50
out of 100
Grade: C-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -21.1% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : TLPH
The strongest argument for TLPH centers on Price/Book.
Bull Case : VTRS
The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.
Bear Case : TLPH
The primary concerns for TLPH are Revenue Growth, EPS Growth, Market Cap.
Bear Case : VTRS
The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
TLPH profiles as a value stock while VTRS is a turnaround play — different risk/reward profiles.
VTRS carries more volatility with a beta of 0.80 — expect wider price swings.
VTRS is growing revenue faster at 5.0% — sustainability is the question.
VTRS generates stronger free cash flow (551M), providing more financial flexibility.
Bottom Line
VTRS scores higher overall (50/100 vs 23/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Talphera Inc.
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Talphera Inc. is a pioneering biotechnology firm specializing in the development of advanced therapies targeting rare diseases and significant unmet medical needs. The company leverages its expertise in peptide-based therapeutics to address critical challenges in cancer treatment and other high-need health areas. With a robust pipeline of innovative therapeutic candidates and a strong dedication to research excellence, Talphera is well-positioned for transformative contributions to the healthcare sector. For institutional investors, Talphera represents a compelling opportunity to engage with a growth-oriented company in the expanding biotechnology landscape.
Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?